KRAS and cancer: Although it remains to be proved, for KRAS-G12C–mutated tumors that express high levels of SRC, optimal therapeutic responses may be obtained by the combination of MRTX849 (or other G12Ci inhibitors), DGY-06-116 (or other SRC inhibitors), and perhaps additional cancer drugs affecting mechanistically distinct circuitries (such as immunotherapies).